ロードアイランドにおけるクローン病の臨床試験
ロードアイランド内の拠点で、クローン病に関する12件の研究が参加者を募集しています。
ロードアイランド内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University Gastroenterology - Providence - West River Street ( Site 5057), Providence
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- University Gastroenterology - Providence - Staniford Street /ID# 280919, Providence
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- University Gastroenterology, Providence
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology, Providence
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology Providence, Providence
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- University Gastroenterology, Providence
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology-Site Number: 8400103, Providence
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology - GI Alliance-Site Number: 8400103, Providence
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University Gastroenterology, Providence
被験者募集中第4相
18歳〜70歳 · 全性別 · 2026/09/09更新 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Gastroenterology Associates, Providence
被験者募集中
18歳以上 · 全性別 · 2026/08/07更新 · NCT05230173Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Rhode Island Hospital, Providence
被験者募集中第4相
6歳〜17歳 · 全性別 · 2026/05/27更新 · NCT05781152A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Providence
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。